Evelyn Cruz-Acuna
Valencia, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.
Journal: American journal of hematology
Published: April 24, 2026
Prognostic impact of immunophenotypic classification for newly diagnosed NPM1-mutated acute myeloid leukemia.
Journal: Cytometry. Part B, Clinical cytometry
Published: June 19, 2025
Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Journal: Cancers
Published: April 25, 2025
Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia.
Journal: Diagnostics (Basel, Switzerland)
Published: March 17, 2025
Validation of pharmacokinetic model for quizartinib quantified by UPLC-MS/MS in patients with FLT3-ITD negative newly diagnosed acute myeloid leukemia.
Journal: European journal of clinical pharmacology
Published: February 19, 2025
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.
Journal: Cancers
Published: October 27, 2024
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Journal: Cancer
Published: August 02, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Journal: The Lancet. Haematology
Published: March 15, 2024
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Journal: Haematologica
Published: March 28, 2022
Last Updated: 09/26/2026